An advisory panel to the Food and Drug Administration (FDA) has recommended broadening access to several popular peptides, including BPC-157, despite strong objections from the FDA's own scientists. In a series of votes, the panel narrowly voted 8-6, with one abstention, in favor of allowing specialized pharmacies to compound these peptides. Each of the seven peptides under review received identical votes, despite FDA scientists presenting analyses that did not support easing restrictions due to concerns about safety, efficacy, contamination risks, allergic reactions, and quality control.
The FDA's staff scientists reiterated their long-standing concerns, highlighting the lack of human data for these substances; most existing evidence is from preclinical animal studies. Official Russell Wesdyk from the FDA noted a "foundational challenge" in defining these peptides, as chemical compositions can vary despite sharing the same name. Concerns were also raised by panel members, such as Dr. Brian Lee, regarding the potential harm of endorsing these products given the limited human data.
Health Secretary Robert F. Kennedy Jr. has publicly supported easing restrictions on peptides, stating he is a "big fan" of them and vowing to overturn Biden administration policies. Industry groups and compounding pharmacies, whose representatives largely comprised the public comment section of the meeting, advocate for greater access, citing a need to move away from the current gray market for these substances.
While the FDA is not legally bound by the advisory committee's recommendations, it typically follows them. The committee's backing represents a significant win for the peptide industry and consumers. Although formal reclassification would require new regulations and could take months or years, some experts believe the most likely immediate outcome is a temporary policy reassuring pharmacies they won't be targeted for compounding these peptides. This could ultimately lead to the outcome Secretary Kennedy desires, according to attorney Nathan Beaver.
Among the peptides reviewed were BPC-157, often used for ulcerative colitis, and KPV, used for inflammation. The panel's recommendations could enable clinicians to prescribe these compounds through U.S. compounding pharmacies, offering more discretion than current narrow indications. However, critics worry that making these products more accessible might mislead the public about the limited available human data.
